Alan Hauser Alan Hauser

Commercializing
innovative genomic tools to enable tomorrow’s treatments

Boosting
Bio-Business Building

I help biotools (omics) companies with:

By applying roadmapping and resource-allocation best practices,

I catapult omics • Innovation to Commercialization (I2C) success.

 

With a focus on pinpointing missing pieces in the I2C puzzle,

I vet new business opportunities in relation to corporate growth plans.

Representative results include:

Beneficial collaborative alliances with preferred partners

Alignment between new product features and customer needs

Freedom-to-Operate (FTO) clearance, a valuable assessment to have even with an already strong patent portfolio

 

Catalyzing omics I2C for propelling precision testing and care